A clinical briefing for providers on Epsolay availability in 2026, including prescribing considerations, access barriers, cost data, and patient resources.
Epsolay (Benzoyl Peroxide cream, 5%) has established itself as a valuable addition to the rosacea treatment armamentarium since its FDA approval in April 2022. As the first and only microencapsulated Benzoyl Peroxide formulation approved for inflammatory lesions of rosacea in adults, it fills a unique therapeutic niche.
However, your patients may be reporting difficulty filling their Epsolay prescriptions. This briefing covers the current availability landscape, prescribing implications, cost considerations, and tools to help your patients access this medication.
Understanding Epsolay's background helps contextualize its current market position:
Epsolay's clinical profile supports its use in appropriate patient populations, but access barriers necessitate proactive planning:
While Epsolay has a favorable interaction profile as a topical agent, remind patients to avoid concurrent use with:
For complete interaction guidance, see our Epsolay drug interactions reference.
Common adverse reactions include application site pain, erythema, pruritus, dryness, scaling, stinging/burning, and swelling. Serious but rare events include hypersensitivity reactions (anaphylaxis, angioedema, urticaria). Advise patients about photosensitivity and the importance of sun protection.
There is no boxed warning. The product is contraindicated only in patients with known hypersensitivity to Benzoyl Peroxide or any formulation component.
Epsolay is not on the FDA drug shortage list as of early 2026. The availability challenges providers and patients encounter are demand-side rather than supply-side:
Cost remains the primary access barrier for many patients. Here's the current pricing landscape:
The Mayne Pharma Patient Savings Card is particularly valuable and should be discussed with patients at the point of prescribing. You can direct patients to epsolay.com/savings-and-support or to our patient-facing guide on saving money on Epsolay.
Important note: Government insurance (Medicare, Medicaid, Tricare) patients are not eligible for manufacturer copay cards. These patients may benefit from patient assistance programs through NeedyMeds.org or RxAssist.org.
Several resources can help streamline Epsolay access for your patients:
Medfinder allows providers and staff to check real-time pharmacy stock for Epsolay and direct patients to pharmacies that have it available. This reduces patient frustration and pharmacy call volume.
When submitting prior authorization requests, emphasize:
If your practice stocks Epsolay samples, consider providing a bridge supply while patients navigate insurance approval or pharmacy sourcing. This helps maintain treatment continuity.
Identify 1-2 local pharmacies (ideally independent or specialty dermatology pharmacies) that reliably stock or can quickly order Epsolay. Route prescriptions to these locations by default to reduce fill failures.
When Epsolay is not accessible or clinically appropriate, evidence-based alternatives include:
See our comprehensive alternatives guide for patient-facing information you can share.
Several developments may improve Epsolay access over time:
Epsolay remains a clinically differentiated treatment for papulopustular rosacea with a favorable safety profile and once-daily convenience. While access challenges persist in 2026, proactive steps — including savings card enrollment, preferred pharmacy routing, and tools like Medfinder — can meaningfully improve the patient experience.
For additional provider resources, including a guide on helping patients find Epsolay in stock and information on helping patients save money on Epsolay, visit our provider section.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
